keyword
MENU ▼
Read by QxMD icon Read
search

Tumor infiltrating lymphocyte breast

keyword
https://www.readbyqxmd.com/read/29893329/the-importance-of-stromal-and-intratumoral-tumor-lymphocyte-infiltration-for-pathologic-complete-response-in-patients-with-locally-advanced-breast-cancer
#1
Melek Karakurt Eryilmaz, Hasan Mutlu, Betül Ünal, Derya Kıvrak Salim, Fatma Yalçın Musri, Hasan Şenol Coşkun
Objective: Increased tumor-infiltrating lymphocytes (TILs) in breast carcinoma tissues is an independent predictive factor for pathologic complete response (pCR). The increased intratumoral and stromal TILs (sTILs) in breast cancer (BC) have significant prognostic effects. In this study, we evaluated whether pCR rates to neoadjuvant chemotherapy (NACT) are higher in tumors with increased number of TILs in the pretreatment biopsy. Materials and Methods: We retrospectively evaluated the number of TILs in intratumoral TILs (iTILs) and sTILs compartments from pretreatment full-face hematoxylin and eosin-stained sections of 62 patients with locally advanced BC (LABC) who received NACT...
April 2018: Journal of Cancer Research and Therapeutics
https://www.readbyqxmd.com/read/29886396/reproducible-evaluation-of-tumor-infiltrating-lymphocytes-tils-using-the-recommendations-of-international-tils-working-group-2014
#2
Yumi A Kojima, Xiaohong Wang, Hongxia Sun, Frances Compton, Michael Covinsky, Songlin Zhang
Tumor infiltrating lymphocytes (TILs) in breast cancer play an important role in predicting the outcome of breast cancer. The goal of our current study is to investigate the consistency and reproducibility of the recommendations published by the International TILs Working Group 2014 among pathology trainees and pathologists. Hematoxylin & Eosin (H&E) slides from 129 breast cancer cases (one slide each) from 2009 to 2014 were evaluated. Each case was blindly and independently reviewed by two observers following the International TILs Working Group 2014 recommendations...
May 31, 2018: Annals of Diagnostic Pathology
https://www.readbyqxmd.com/read/29883779/tumor-infiltrating-lymphocyte-volume-is-a-better-predictor-of-neoadjuvant-therapy-response-and-overall-survival-in-triple-negative-invasive-breast-cancer
#3
Lin Zhang, Xiaohong I Wang, Songlin Zhang
Triple-negative breast cancer (TNBC) has an aggressive behavior, limited therapeutic options, and high mortality rate. Neoadjuvant chemotherapy (NACT) is a standard treatment for TNBC and patients with pathological complete response (pCR) have a favorable outcome. We conducted a comprehensive evaluation of cancer clinicopathologic parameters, and correlated these parameters with the pCR rate and the overall survival. Fifty-eight patients with TNBC of no special type who underwent breast biopsy, neoadjuvant therapy, and mastectomy in our institution during 2005-2016 were included in this study...
June 5, 2018: Human Pathology
https://www.readbyqxmd.com/read/29880480/macrophages-promote-circulating-tumor-cell-mediated-local-recurrence-following-radiation-therapy-in-immunosuppressed-patients
#4
Marjan Rafat, Todd A Aguilera, Marta Vilalta, Laura L Bronsart, Luis A Soto, Rie von Eyben, Meghana A Golla, Yasaman Ahrari, Stavros Melemenidis, Anosheh Afghahi, Melissa J Jenkins, Allison W Kurian, Kathleen Horst, Amato J Giaccia, Edward E Graves
Although radiation therapy (RT) decreases the incidence of locoregional recurrence in breast cancer, patients with triple-negative breast cancer (TNBC) have increased risk of local recurrence following breast-conserving therapy (BCT). The relationship between RT and local recurrence is unknown. Here we tested the hypothesis that recurrence in some instances is due to the attraction of circulating tumor cells to irradiated tissues. To evaluate the effect of absolute lymphocyte count on local recurrence after RT in TNBC patients, we analyzed radiation effects on tumor and immune cell recruitment to tissues in an orthotopic breast cancer model...
June 7, 2018: Cancer Research
https://www.readbyqxmd.com/read/29869774/comparison-of-tumor-infiltrating-lymphocytes-of-breast-cancer-in-core-needle-biopsies-and-resected-specimens-a-retrospective-analysis
#5
Yoon Jin Cha, Sung Gwe Ahn, Soong June Bae, Chang Ik Yoon, Jayeong Seo, Woo Hee Jung, Eun Ju Son, Joon Jeong
PURPOSE: Neoadjuvant chemotherapy (NAC) is being increasingly used to treat locally advanced breast cancer and to conserve the breast. In triple-negative breast cancer and HER2-positive breast cancer, a high density of tumor-infiltrating lymphocytes (TILs) is an important predictor of NAC response. Thus far, it remains unclear whether the TIL scores in core needle biopsies (CNBs) are closely representative of those in the whole tumor section in resected specimens. This study aimed to evaluate the concordance between the TIL scores of CNBs and resected specimens of breast cancer...
June 5, 2018: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/29867227/immune-recognition-of-somatic-mutations-leading-to-complete-durable-regression-in-metastatic-breast-cancer
#6
Nikolaos Zacharakis, Harshini Chinnasamy, Mary Black, Hui Xu, Yong-Chen Lu, Zhili Zheng, Anna Pasetto, Michelle Langhan, Thomas Shelton, Todd Prickett, Jared Gartner, Li Jia, Katarzyna Trebska-McGowan, Robert P Somerville, Paul F Robbins, Steven A Rosenberg, Stephanie L Goff, Steven A Feldman
Immunotherapy using either checkpoint blockade or the adoptive transfer of antitumor lymphocytes has shown effectiveness in treating cancers with high levels of somatic mutations-such as melanoma, smoking-induced lung cancers and bladder cancer-with little effect in other common epithelial cancers that have lower mutation rates, such as those arising in the gastrointestinal tract, breast and ovary1-7 . Adoptive transfer of autologous lymphocytes that specifically target proteins encoded by somatically mutated genes has mediated substantial objective clinical regressions in patients with metastatic bile duct, colon and cervical cancers8-11 ...
June 2018: Nature Medicine
https://www.readbyqxmd.com/read/29866579/hot-spot-and-whole-tumor-enumeration-of-cd8-tumor-infiltrating-lymphocytes-utilizing-digital-image-analysis-is-prognostic-in-triple-negative-breast-cancer
#7
Patrick J McIntire, Lina Irshaid, Yifang Liu, Zhengming Chen, Faith Menken, Eugene Nowak, Sandra J Shin, Paula S Ginter
BACKGROUND: CD8+ tumor-infiltrating lymphocytes (TILs) have emerged as a prognostic indicator in triple-negative breast cancer (TNBC). There is debate surrounding the prognostic value of hot spots for CD8+ TIL enumeration. METHODS: We compared hot spot versus whole-tumor CD8+ TIL enumeration in prognosticating TNBC using immunohistochemistry on whole tissue sections and quantification by digital image analysis (Halo imaging analysis software; Indica Labs, Corrales, NM)...
May 7, 2018: Clinical Breast Cancer
https://www.readbyqxmd.com/read/29858752/the-combined-presence-of-cd20-b-cells-and-pd-l1-tumor-infiltrating-lymphocytes-in-inflammatory-breast-cancer-is-prognostic-of-improved-patient-outcome
#8
H Arias-Pulido, A Cimino-Mathews, N Chaher, C Qualls, N Joste, C Colpaert, J D Marotti, M Foisey, E R Prossnitz, L A Emens, S Fiering
PURPOSE: The purpose of the study was to evaluate protein expression of PD-L1 and CD20 as prognostic biomarkers of patient outcome in inflammatory breast cancer (IBC) samples. METHODS: PD-L1 and CD20 protein expression was measured by immunohistochemistry in 221 pretreatment IBC biopsies. PD-L1 was assessed in tumor cells (PD-L1+ tumor cells) and tumor stromal infiltrating lymphocytes (PD-L1+ TILs); CD20 was scored in tumor-infiltrating B cells. Kaplan-Meier curves and Cox proportional hazard models were used for survival analysis...
June 1, 2018: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/29788230/tumor-infiltrating-lymphocytes-in-patients-receiving-trastuzumab-pertuzumab-based-chemotherapy-a-tryphaena-substudy
#9
Michail Ignatiadis, Gert Van den Eynden, Salgado Roberto, Marco Fornili, Yacine Bareche, Christine Desmedt, Françoise Rothé, Marion Maetens, David Venet, Esther Holgado, Virginia McNally, Astrid Kiermaier, Heidi M Savage, Timothy R Wilson, Javier Cortes, Andreas Schneeweiss, Karen Willard-Gallo, Elia Biganzoli, Christos Sotiriou
Background: There is an urgent requirement to identify biomarkers to tailor treatment in human epidermal growth factor receptor 2 (HER2)-amplified early breast cancer treated with trastuzumab/pertuzumab-based chemotherapy. Methods: Among the 225 patients randomly assigned to trastuzumab/pertuzumab concurrently or sequentially with an anthracycline-containing regimen or concurrently with an anthracycline-free regimen in the Tryphaena trial, we determined the percentage of tumor-infiltrating lymphocytes (TILs) at baseline in 213 patients, of which 126 demonstrated a pathological complete response (pCR; ypT0/is ypN0), with 28 demonstrating event-free survival (EFS) events...
May 18, 2018: Journal of the National Cancer Institute
https://www.readbyqxmd.com/read/29765252/triple-negative-and-her2-overexpressing-breast-cancer-cell-sialylation-impacts-tumor-microenvironment-t-lymphocyte-subset-recruitment-a-possible-mechanism-of-tumor-escape
#10
Christian Garbar, Corinne Mascaux, Yacine Merrouche, Armand Bensussan
Introduction: Breast cancers develop different patterns of sialylation to modulate their tumor-infiltrating lymphocyte (TIL) environment. We studied the relationship between α-2,6 sialyltransferases and the TIL in different breast cancer molecular subgroups. Materials and methods: Immunohistochemical preparations were made from 39 luminal (LUM), 13 human epidermal growth factor receptor 2-overexpressing (HER2) and 47 triple-negative (TN) breast carcinomas. Targeted proteins included ST6Gal-I, ST6Gal-II, ST6GalNac-I, CD8, CD4 and granzyme-B in both cytotoxic T lymphocytes and NK lymphocytes (CTL/NK)...
2018: Cancer Management and Research
https://www.readbyqxmd.com/read/29765119/elucidation-of-inhibitory-effects-on-metastatic-sentinel-lymph-nodes-of-breast-cancer-during-one-step-nucleic-acid-amplification
#11
Yoshiya Horimoto, Masahiko Tanabe, Saiko Kazuno, Yoshiki Miura, Kaoru Mogushi, Hiroshi Sonoue, Atsushi Arakawa, Kazunori Kajino, Toshiyuki Kobayashi, Mitsue Saito
One-step nucleic acid amplification (OSNA) is an established method for intraoperative diagnosis of breast cancer metastasis in sentinel lymph nodes, based on quantification of CK19 mRNA, specific to breast epithelial cells. Inhibitors interfere with the PCR amplification process of PCR. Thus, OSNA, based on gene amplification without RNA purification, might be impacted by numerous factors persisting in a sample, and thereby potentially acting as PCR inhibitors. However, neither the characteristics of breast cancers showing inhibitory effects during OSNA, nor any of the possible inhibitors, have as yet been identified...
May 15, 2018: Scientific Reports
https://www.readbyqxmd.com/read/29764038/-expression-and-distribution-of-programmed-death-receptor-1-and-t-cell-immunoglobulin-mucin-3-in-breast-cancer-microenvironment-and-its-relationship-with-clinicopathological-features
#12
H Shen, H Sheng, J J Lu, C Feng, M Yao, H Pan, L S Xu, J F Shen, Y Zheng, Y L Zhou
Objective: To explore the expression and distribution of programmed death receptor 1 (PD-1) and T-cell immunoglobulin mucin 3 (TIM-3) in breast cancer microenvironment and analyze the their correlation with the clinicopathological features. Methods: The specimens of tumor tissue and adjacent tissues from 30 patients with infiltrative breast cancer who were diagnosed as breast cancer from June 2016 to May 2017 in The First Hospital of Jiaxing were collected, and the specimen were divided into two parts along the center...
May 8, 2018: Zhonghua Yi Xue za Zhi [Chinese medical journal]
https://www.readbyqxmd.com/read/29754847/feasibility-of-classification-of-triple-negative-breast-cancer-by-immunohistochemical-surrogate-markers
#13
Sewha Kim, Byung-In Moon, Woosung Lim, Sanghui Park, Min Sun Cho, Sun Hee Sung
INTRODUCTION: Recently, Burstein et al identified 4 stable molecular subtypes of triple negative breast cancer (TNBC) by mRNA profiling: luminal androgen receptor (LAR), mesenchymal (MES), basal-like immune-activated (BLIA), and basal-like immune-suppressive (BLIS) types. The purpose of this study was to assess the feasibility of immunohistochemistry (IHC) surrogate panel in classifying the TNBC molecular subtypes using a large cohort of TNBC retrieved from a single institution. MATERIALS AND METHODS: IHC for androgen receptor [AR], claudin-3, E-cadherin, cytokeratin 5/6 [CK5/6], epidermal growth factor receptor [EGFR], indoleamine 2,3-dioxygenase 1 [IDO1], and Forkhead box C1 [FOXC1] were performed using the tissue microarray constructed from 200 TNBC samples...
March 23, 2018: Clinical Breast Cancer
https://www.readbyqxmd.com/read/29750542/the-critical-clinical-role-of-interferon-beta-in-regulating-cancer-stem-cell-properties-in-triple-negative-breast-cancer
#14
Mary R Doherty, Mark W Jackson
Triple-negative breast cancer (TNBC) the deadliest form of this disease currently lacks a targeted therapy and is characterized by increased risk of metastasis and presence of therapeutically resistant cancer stem cells (CSC). Recent evidence has demonstrated that the presence of an interferon (IFN)/signal transducer of activated transcription 1 (STAT1) gene signature correlates with improved therapeutic response and overall survival in TNBC patients. In agreement with these clinical observations, our recent work has demonstrated, in a cell model of TNBC that CSC have intrinsically repressed IFN signaling...
May 11, 2018: DNA and Cell Biology
https://www.readbyqxmd.com/read/29736741/homologous-recombination-deficiency-and-host-anti-tumor-immunity-in-triple-negative-breast-cancer
#15
REVIEW
M L Telli, D G Stover, S Loi, S Aparicio, L A Carey, S M Domchek, L Newman, G W Sledge, E P Winer
PURPOSE: Triple-negative breast cancer (TNBC) is associated with worse outcomes relative to other breast cancer subtypes. Chemotherapy remains the standard-of-care systemic therapy for patients with localized or metastatic disease, with few biomarkers to guide benefit. METHODS: We will discuss recent advances in our understanding of two key biological processes in TNBC, homologous recombination (HR) DNA repair deficiency and host anti-tumor immunity, and their intersection...
May 7, 2018: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/29725336/tribody-her2-2-xcd16-is-more-effective-than-trastuzumab-in-enhancing-%C3%AE-%C3%AE-t-cell-and-natural-killer-cell-cytotoxicity-against-her2-expressing-cancer-cells
#16
Hans H Oberg, Christian Kellner, Daniel Gonnermann, Susanne Sebens, Dirk Bauerschlag, Martin Gramatzki, Dieter Kabelitz, Matthias Peipp, Daniela Wesch
An enhanced expression of human epidermal growth factor receptor 2 (HER2, ErbB2) often occurs in an advanced stage of breast, ovarian, gastric or esophageal cancer, and pancreatic ductal adenocarcinoma (PDAC). Commonly, HER2 expression is associated with poor clinical outcome or chemoresistance in ovarian and breast cancer patients. Treatment with humanized anti-HER2 monoclonal antibodies, such as trastuzumab or pertuzumab, has improved the outcome of patients with HER2-positive metastatic gastric or breast cancer, but not all patients benefit...
2018: Frontiers in Immunology
https://www.readbyqxmd.com/read/29721371/complimentary-mechanisms-of-dual-checkpoint-blockade-expand-unique-t-cell-repertoires-and-activate-adaptive-anti-tumor-immunity-in-triple-negative-breast-tumors
#17
Erika J Crosby, Junping Wei, Xiao Yi Yang, Gangjun Lei, Tao Wang, Cong-Xiao Liu, Pankaj Agarwal, Alan J Korman, Michael A Morse, Kenneth Gouin, Simon R V Knott, H Kim Lyerly, Zachary C Hartman
Triple-negative breast cancer (TNBC) is an aggressive and molecularly diverse breast cancer subtype typified by the presence of p53 mutations (∼80%), elevated immune gene signatures and neoantigen expression, as well as the presence of tumor infiltrating lymphocytes (TILs). As these factors are hypothesized to be strong immunologic prerequisites for the use of immune checkpoint blockade (ICB) antibodies, multiple clinical trials testing single ICBs have advanced to Phase III, with early indications of heterogeneous response rates of <20% to anti-PD1 and anti-PDL1 ICB...
2018: Oncoimmunology
https://www.readbyqxmd.com/read/29721370/a-pi3k-p110%C3%AE-selective-inhibitor-enhances-the-efficacy-of-anti-her2-neu-antibody-therapy-against-breast-cancer-in-mice
#18
Jae-Hyeog Choi, Ki Hyang Kim, Kug-Hwan Roh, Hana Jung, Anbok Lee, Ji-Young Lee, Joo Yeon Song, Seung Jae Park, Ilhwan Kim, Won-Sik Lee, Su-Kil Seo, Il-Whan Choi, Yang-Xin Fu, Sung Su Yea, SaeGwang Park
Combination therapies with phosphoinositide 3-kinase (PI3K) inhibitors and trastuzumab (anti-human epidermal growth factor receptor [HER]2/neu antibody) are effective against HER2+ breast cancer. Isoform-selective PI3K inhibitors elicit anti-tumor immune responses that are distinct from those induced by inhibitors of class I PI3K isoforms (pan-PI3K inhibitors). The present study investigated the therapeutic effect and potential for stimulating anti-tumor immunity of combined therapy with an anti-HER2/neu antibody and pan-PI3K inhibitor (GDC-0941) or a PI3K p110α isoform-selective inhibitor (A66) in mouse models of breast cancer...
2018: Oncoimmunology
https://www.readbyqxmd.com/read/29715119/eribulin-promotes-antitumor-immune-responses-in-patients-with-locally-advanced-or-metastatic-breast-cancer
#19
Wataru Goto, Shinichiro Kashiwagi, Yuka Asano, Koji Takada, Tamami Morisaki, Hisakazu Fujita, Tsutomu Takashima, Masahiko Ohsawa, Kosei Hirakawa, Masaichi Ohira
BACKGROUND/AIM: Several proteins involved in immune regulation and the relationship among these, the tumor microenvironment, and clinical outcomes of eribulin treatment were evaluated in advanced or metastatic breast cancer patients. PATIENTS AND METHODS: This retrospective cohort study comprised 52 eribulin-treated locally advanced or metastatic breast cancer patients. Cancer tissue samples were obtained before and after treatment in 10 patients. Immunohistochemistry was performed to determine programmed death (PD)-1, CD8, and forkhead box P3 (FOXP3) expression by stromal tumor-infiltrating lymphocytes, and PD-ligand (L1) and PD-L2 expression by cancer cells...
May 2018: Anticancer Research
https://www.readbyqxmd.com/read/29698574/n-glycan-signatures-identified-in-tumor-interstitial-fluid-and-serum-of-breast-cancer-patients-association-with-tumor-biology-and-clinical-outcome
#20
Thilde Terkelsen, Vilde D Haakensen, Radka Saldova, Pavel Gromov, Merete Kjaer Hansen, Henning Stöckmann, Ole Christian Lingjaerde, Anne-Lise Børresen-Dale, Elena Papaleo, Åslaug Helland, Pauline M Rudd, Irina Gromova
Particular N-glycan structures are known to be associated with breast malignancies by coordinating various regulatory events within the tumor and corresponding microenvironment, thus implying that N-glycan patterns may be used for cancer stratification and as predictive or prognostic biomarkers. However, the association between N-glycans secreted by breast tumor and corresponding clinical relevance remain to be elucidated. We profiled N-glycans by HILIC UPLC across a discovery dataset composed of tumor interstitial fluids (TIF, n=85), paired normal interstitial fluids (NIF, n=54) and serum samples (n=28) followed by independent evaluation, with the ultimate goal of identifying tumor-related N-glycan patterns in blood of breast cancer patients...
April 26, 2018: Molecular Oncology
keyword
keyword
56488
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"